In two phase 3 clinical trials, retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon triple-hormone receptor agonist, demonstrated significant weight loss and clinically meaningful improvements in health outcomes in people living with obesity and type 2 diabetes
Or squeeze in small bouts of movement even when you cant make time for a long workout
My view is that the pronounced effect of GLP-1 analogues on gastric emptying is not only an important mediator of satiety and reduced food intake but also a likely mechanism responsible for its effect on type 2 diabetes and cardiovascular disease
1 They represent a fundamental shift in the drug supply chain, a hybrid model designed to bridge the gap between traditional, patient-specific compounding and large-scale pharmaceutical manufacturing
Communicate with your provider: Don't suffer in silence
Jeff Atlas, PA-C, manages peptide protocols and performs injections at Formation